Table 2.
Temporal evolution of MR imaging in tumors without progression
| Pre-SBRT n = 96 | 1 months n = 96 | 3 months n = 96 | 6 months n = 96 | 9 months n = 78 | 12 months n = 66 |
> 12 months n = 55 | |
|---|---|---|---|---|---|---|---|
| Enhancement patterns | |||||||
| APHE and washout | 96 (100) | 57 (59) | 25 (26) | 11 (11) | 4 (5) | 3 (5) | 1 (2) |
| Non-enhancement | 0 | 10 (10) | 19 (20) | 20 (21) | 14 (18) | 12 (18) | 12 (22) |
| Delayed enhancement | 0 | 29 (30) | 52 (54) | 65 (68) | 60 (77) | 51 (77) | 42 (76) |
| T1WI | |||||||
| Hypointense | 90 (94) | 29 (30) | 4 (4) | 1 (1) | 1 (1) | 1 (2) | 0 (0) |
| Iso-hypointense | 6 (6) | 67 (70) | 70 (73) | 70 (73) | 57 (73) | 49 (74) | 43 (78) |
| Isointense | 0 | 0 | 22 (23) | 25 (26) | 20 (26) | 16 (24) | 12 (22) |
| T2WI | |||||||
| Hyperintense | 93 (97) | 44 (46) | 9 (9) | 3 (3) | 1 (1) | 0 (0) | 0 |
| Iso-hyperintense | 3 (3) | 46 (48) | 62 (65) | 49 (51) | 34 (44) | 27 (41) | 20 (36) |
| Isointense | 0 | 6 (6) | 25 (26) | 44 (46) | 43 (55) | 39 (59) | 35 (64) |
| DWI | |||||||
| Hyperintense | 92 (96) | 27 (28) | 6 (6) | 0 | 0 | 0 | 0 |
| Iso-hyperintense | 4 (4) | 58 (60) | 48 (50) | 26 (27) | 12 (15) | 8 (12) | 7 (13) |
| Isointense | 0 | 11 (11) | 42 (44) | 70 (73) | 66 (85) | 58 (88) | 48 (87) |
Data are N(%). Percentile data may not sum to 100% due to rounding. Percentage data may not sum up to 100% due to approximations
SBRT stereotactic body radiation therapy; APHE arterial phase hyperenhancement; MRI magnetic resonance imaging; T1WI. T1-weighted imaging; T2WI T2-weighted imaging; DWI diffusion-weighted imaging